Although preclinical studies have demonstrated promising results, clinical studies support the efficacy of vismodegib in combination with conventional chemotherapies for the treatment of relapsed or refractory HH-driven medulloblastoma pediatric patients [52] and for a subset of medulloblastoma tumors with PTCH and/or SMO mutations [53]. Here, PTCH1 is linked to medulloblastoma.